• Something wrong with this record ?

Recent pharmacological approaches for the treatment of renal cell carcinoma

A. Alimohammadi, H. Fajkovic, M. Remzi, S. Shariat, M. Schmidinger

. 2022 ; 15 (2) : 187-195. [pub] 20220322

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22019427

INTRODUCTION: Therapies combining either two immune check-point inhibitors (ICIs) or an ICI and a tyrosine kinase inhibitor (TKI) have been shown to improve overall survival (OS), progression-free survival (PFS) and objective response rates (ORR) in metastatic renal cell carcinoma (mRCC); moreover, unprecedented rates of complete remission (CR) have been reported. AREAS COVERED: Among six randomized trials of ICI combinations, four have outperformed the TKI sunitinib in terms of OS. The CheckMate 214 trial investigated the combination of nivolumab (a programmed cell death protein 1 [PD-1] inhibitor) and ipilimumab (a cytotoxic T-lymphocyte antigen-4 [CTLA-4)] inhibitor). Three other trials evaluated combinations of an ICI and a TKI. These combinations are: 1) pembrolizumab (PD-1 inhibitor) plus axitinib, 2) nivolumab plus cabozantinib, and 3) pembrolizumab plus lenvatinib. This short review addresses the findings of these trials, comparing outcomes and discussing the challenges of decision-making in clinical practice. EXPERT OPINION: Not all patients benefit from ICI combinations. Predictive biomarkers and new therapeutic approaches are urgently needed to overcome treatment failures. A growing understanding of immune escape mechanisms and the interplay between the immune response and the gut microbiota may offer additional rescue strategies beyond ICIs and TKIs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019427
003      
CZ-PrNML
005      
20220804135640.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/17512433.2022.2053521 $2 doi
035    __
$a (PubMed)35285369
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Alimohammadi, Arman $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
245    10
$a Recent pharmacological approaches for the treatment of renal cell carcinoma / $c A. Alimohammadi, H. Fajkovic, M. Remzi, S. Shariat, M. Schmidinger
520    9_
$a INTRODUCTION: Therapies combining either two immune check-point inhibitors (ICIs) or an ICI and a tyrosine kinase inhibitor (TKI) have been shown to improve overall survival (OS), progression-free survival (PFS) and objective response rates (ORR) in metastatic renal cell carcinoma (mRCC); moreover, unprecedented rates of complete remission (CR) have been reported. AREAS COVERED: Among six randomized trials of ICI combinations, four have outperformed the TKI sunitinib in terms of OS. The CheckMate 214 trial investigated the combination of nivolumab (a programmed cell death protein 1 [PD-1] inhibitor) and ipilimumab (a cytotoxic T-lymphocyte antigen-4 [CTLA-4)] inhibitor). Three other trials evaluated combinations of an ICI and a TKI. These combinations are: 1) pembrolizumab (PD-1 inhibitor) plus axitinib, 2) nivolumab plus cabozantinib, and 3) pembrolizumab plus lenvatinib. This short review addresses the findings of these trials, comparing outcomes and discussing the challenges of decision-making in clinical practice. EXPERT OPINION: Not all patients benefit from ICI combinations. Predictive biomarkers and new therapeutic approaches are urgently needed to overcome treatment failures. A growing understanding of immune escape mechanisms and the interplay between the immune response and the gut microbiota may offer additional rescue strategies beyond ICIs and TKIs.
650    _2
$a axitinib $x terapeutické užití $7 D000077784
650    12
$a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
650    _2
$a lidé $7 D006801
650    _2
$a ipilimumab $x terapeutické užití $7 D000074324
650    12
$a nádory ledvin $x farmakoterapie $x patologie $7 D007680
650    _2
$a sunitinib $x terapeutické užití $7 D000077210
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fajkovic, Harun $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Remzi, Mesut $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Shariat, Shahrokh $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Schmidinger, Manuela $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00174410 $t Expert review of clinical pharmacology $x 1751-2441 $g Roč. 15, č. 2 (2022), s. 187-195
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35285369 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135634 $b ABA008
999    __
$a ok $b bmc $g 1822852 $s 1170670
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 15 $c 2 $d 187-195 $e 20220322 $i 1751-2441 $m Expert review of clinical pharmacology $n Expert Rev Clin Pharmacol $x MED00174410
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options